RVPH

Analyst Rating Changes: Goldman Sachs downgraded Genuine Parts Company and raised Ulta Beauty's price target, while Needham cut Vaxcyte's target but maintained a Buy rating. Other notable changes include TD Securities upgrading First Watch Restaurant Group and B of A Securities downgrading Knight-Swift Transportation Holdings.

Stock Performance: Various companies experienced significant fluctuations in their stock prices, with Genuine Parts closing at $119.14, Ulta Beauty at $366.54, and Delta Air Lines at $43.60, reflecting the impact of recent analyst ratings on market performance.

Brilaroxazine Efficacy and Safety: Reviva Pharmaceuticals reported favorable long-term safety and efficacy results for brilaroxazine in treating schizophrenia, with significant improvements in PANSS scores sustained over one year during the open-label extension trial.

Future Developments: The company plans to initiate the Phase 3 RECOVER-2 trial by mid-2025, with full data from the ongoing studies expected in Q2 2025 and a potential New Drug Application submission targeted for Q4 2026.

Reviva Pharmaceuticals Announcement: Reviva Pharmaceuticals Holdings, Inc. has announced the presentation of topline data from the Phase 3 RECOVER study on brilaroxazine for schizophrenia at the 2025 Congress of the Schizophrenia International Research Society in Chicago.

Company Overview: Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs, particularly in CNS, inflammatory, and cardiometabolic diseases, with two drug candidates currently in its pipeline.

Unusual Options Activity: Several companies, including iRobot (IRBT), Reviva Pharmaceuticals (RVPH), and CVS Health (CVS), are noted for their unusual total active option classes on January 6th.

Investment Insights Tool: TipRanks offers a Smart Score tool to help investors identify top-performing stocks and compare their picks with Wall Street analysts' recommendations.

Reviva Pharmaceuticals Participation: Reviva Pharmaceuticals Holdings, Inc. will have its CEO, Laxminarayan Bhat, participate in a panel discussion at the 2025 BIO CEO & Investor Conference on February 11, 2025, focusing on mental health advancements.

Company Overview: Reviva is a late-stage biopharmaceutical company developing therapies for unmet medical needs, particularly in CNS, inflammatory, and cardiometabolic diseases, with two drug candidates currently in its pipeline.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

Leadership Changes at Applied Therapeutics: Dr. Shoshana Shendelman has stepped down as CEO, with Les Funtleyder appointed as Interim CEO and John H. Johnson named Executive Chairman, aiming to leverage their extensive industry experience to drive the company forward.

Business Updates and Regulatory Developments: The company is addressing a Complete Response Letter from the FDA regarding its drug govorestat for Classic Galactosemia and has withdrawn its Marketing Authorization Application in Europe, while planning to submit a new drug application for Sorbitol Dehydrogenase Deficiency after Q1 2025.

Mitek Systems Performance: Mitek Systems, Inc. shares surged 18.8% in pre-market trading after reporting fourth-quarter earnings of 33 cents per share, significantly exceeding the analyst estimate of 17 cents, along with sales of $43.222 million surpassing expectations.

Stock Movements: Several stocks experienced notable pre-market movements, with Syntec Optics Holdings gaining 59%, while Reviva Pharmaceuticals saw a decline of 29.6% following an announcement of a public offering.

Public Offering Announcement: Reviva Pharmaceuticals has priced an underwritten public offering of 12 million shares of common stock, along with series A and B warrants, aiming to raise approximately $18 million for research and development and general corporate purposes.

Company Overview: Reviva is a late-stage biopharmaceutical company focused on developing therapies for central nervous system, inflammatory, and cardiometabolic diseases, with two drug candidates currently in its pipeline.

Study Results: Reviva Pharmaceuticals announced preliminary data from its Phase 3 RECOVER study, indicating that brilaroxazine demonstrated favorable long-term safety and efficacy in treating schizophrenia over a one-year period across three different doses.

Future Expectations: The company plans to release the full dataset, including additional measures of efficacy, in the first quarter of 2025, while its stock is currently trading at $2.57, reflecting a slight decline.

Brilaroxazine Efficacy and Safety: Preliminary data from the Phase 3 RECOVER study indicates that once-daily brilaroxazine shows robust long-term efficacy and a favorable safety profile in treating schizophrenia, with significant reductions in major symptom domains sustained over one year.

Future Data Expectations: Reviva Pharmaceuticals plans to release the full dataset from the open-label extension of the study in Q1 2025, which will include comprehensive safety, tolerability, and efficacy information.

Clinical Trial Progress: Reviva Pharmaceuticals has reported that 108 patients have completed a one-year treatment in their open-label extension trial for brilaroxazine, aimed at treating schizophrenia, with topline data expected in December 2024 and full analysis in Q1 2025.

Financial Performance: The company reported a net loss of approximately $8.4 million for Q3 2024, an improvement from the previous year's loss, while cash reserves decreased significantly to about $5.6 million as of September 30, 2024.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Community of Traders: The platform boasts a community of over 10,000 serious traders who benefit from exclusive stories and accurate market intelligence provided by Benzinga reporters.

Reviva Pharmaceuticals Announcement: Reviva Pharmaceuticals will present positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial at the CNS Summit 2024 in Boston on November 12th.

Company Overview: Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs, particularly in CNS, inflammatory, and cardiometabolic diseases, with two drug candidates currently in their pipeline.

FDA Approval of Cobenfy: The FDA has approved Bristol Myers Squibb's Cobenfy, an oral medication for schizophrenia in adults, which may benefit Reviva Pharmaceuticals' Brilaroxazine due to its broader receptor targeting and potential cognitive advantages.

Comparison of Treatments: While both Cobenfy and Brilaroxazine address positive and negative symptoms of schizophrenia, Brilaroxazine is designed to reduce metabolic side effects and enhance cognitive function, potentially giving it an edge in treatment effectiveness.

Reviva Pharmaceuticals Participation: Reviva Pharmaceuticals Holdings, Inc. will have its CEO, Laxminarayan Bhat, participate in a panel discussion at the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York City.

Company Overview: Reviva is a late-stage biopharmaceutical company focused on developing therapies for central nervous system, inflammatory, and cardiometabolic diseases, with two drug candidates, brilaroxazine and RP1208, currently in its pipeline.

Reviva Pharmaceuticals Announcement: Reviva Pharmaceuticals will participate in the Lytham Partners Fall 2024 Investor Conference with a webcast presentation by CEO Laxminarayan Bhat on October 1, 2024, at 3:30 p.m. ET.

Company Overview: Reviva is a late-stage biopharmaceutical company focused on developing therapies for central nervous system, inflammatory, and cardiometabolic diseases, with two drug candidates currently in its pipeline.

EF Hutton Coverage Initiation: On September 23, 2024, EF Hutton initiated coverage of Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) with a Buy recommendation, projecting a significant upside of 1,124.00% based on an average one-year price target of $15.30/share from its current price of $1.25/share.

Institutional Ownership Trends: There has been an increase in institutional ownership of Reviva Pharmaceuticals, with 50 funds reporting positions and total shares owned increasing by 23.30% over the last three months, despite some firms reducing their portfolio allocations significantly.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.